Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to determine response rates (partial and complete responses) to nivolumab of recurrent or progressive IDH mutant (grades 2, 3 or 4) gliomas with prior exposure to alkylating agents.


Clinical Trial Description

Gliomas are the most common malignant primary brain tumor in adults. Their clinical presentation is heterogeneous and prognosis is dependent on both the grade of the tumor and the molecular subtype. Somatic mutations in Isocitrate dehydrogenase 1 (IDH1) or, less commonly, Isocitrate dehydrogenase 2 (IDH2) genes have emerged as an important prognostic factor in gliomas and are associated with longer survival. Regardless of initial grade, recurrence and transformation into higher grade tumors is almost universal. There is high unmet medical need in treating recurrent gliomas as there is currently no established standard of care therapy. Recent trials of IDH inhibitors in IDH mutant gliomas and programmed cell death protein 1 (PD-1) and PD-L1 inhibitors in recurrent gliomas have been disappointing. Multiple studies in other cancers have demonstrated that hypermutated tumors are associated with response to immunotherapeutic agents, including anti-CTLA4 agents in melanoma, anti-PD1 therapy in bladder cancer, and anti-programmed-cell-death protein 1 (anti-PD1) therapy in lung, and colorectal cancer. There is evidence to suggest that gliomas with somatic IDH mutations are more prone to develop hypermutation after exposure to alkylating agents than IDH wildtype tumors, providing strong scientific rationale for establishing nivolumab as a treatment option in this subgroup of patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03557359
Study type Interventional
Source Columbia University
Contact
Status Active, not recruiting
Phase Phase 2
Start date June 12, 2018
Completion date December 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03952598 - Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy N/A
Not yet recruiting NCT01445691 - More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery Phase 2
Terminated NCT01251913 - A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes
Withdrawn NCT01961934 - C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression Phase 2/Phase 3
Recruiting NCT01655927 - Efficacy of Tranexamic Acid in Brain Tumor Resections Phase 3
Completed NCT01225003 - Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas N/A
Completed NCT01144247 - Cellular Immunotherapy Study for Brain Cancer Phase 1
Completed NCT00967577 - 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors Phase 1
Terminated NCT01517776 - Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents Phase 2
Completed NCT00832598 - [18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors N/A
Completed NCT00589706 - A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas Phase 2
Completed NCT03154996 - Chronic Convection Enhanced Delivery of Topotecan Phase 1
Withdrawn NCT05054400 - Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR Early Phase 1
Recruiting NCT03091270 - ZOOMit-fMRI Identifies Motor Functional Cortex
Completed NCT00200161 - Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma Phase 2
Terminated NCT02332889 - Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs Phase 1/Phase 2
Recruiting NCT05804227 - Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults Early Phase 1